Table 3.
Selected clinical trials for FGFR1 in SCC
| Drug | Target(s) | Phase | Identifier* |
|---|---|---|---|
| Nintedanib (BIBF 1120) | VEGFR, PDGFR, and FGFR | I/II | NCT01346540 |
| II | NCT01948141 | ||
| Ponatinib | Multitargeting tyrosine kinase | II/III | NCT01761747 |
| II | NCT01935336 | ||
| AZD4547 | FGFR1–4, VEGF4 | I | NCT00979134 |
| II | NCT01795768 | ||
| II/III | NCT02154490 | ||
| I/II | NCT01824901 |
Note:
*
Identifier from ClinicalTrials.gov.
Abbreviations: FGFR1, fibroblast growth factor receptor I; SCC, squamous cell carcinoma; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor.